Grifols A : Q4 2022: sales momentum, in-line adj. EBITDA and material deleverage. Management plays FY 2023 guidance safe, somewhat below expected
>Plasma collection recovery keeps driving sales momentum (+35% y-o-y) - Q4 group sales grew by 35% (+21% cc) reaching € 1.7bn, a touch ahead of our numbers and the consensus. Biopharma posted a robust +45% y-o-y growth (+35% lfl , +14% cc) to € 1.3bn driven by: i/ an upturn in plasma collection (+25% FY 2022 vs FY 2021) helped by the US southern border re-opening, ii/ robust IGg demand and price upticks, iii/ favourable customer mix and competitor shortage in AAT, iv/...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.